Manufacturers across industries are embracing automation to improve productivity, increase resilience and address ongoing labor shortages. Pharmaceutical manufacturing is moving in the same direction, but the path is a bit different.

Unlike many manufacturing environments, pharmaceutical operations cannot simply install new technology and refine it over time. Every change to a production process must be validated to demonstrate that it consistently meets stringent quality and regulatory requirements. Patient safety is always the priority, which naturally makes manufacturers more cautious about adopting any new technologies.

That doesn't mean automation is slowing down in life sciences and pharma, however. In fact, quite the opposite is happening.

Today, a combination of workforce shortages, supply chain disruption, reshoring initiatives and increasing demand for medicines is accelerating investment in automation across the industry. Companies are exploring everything from automated material-handling to advanced planning systems, digital twins and predictive analytics to improve operational agility while maintaining compliance.

The key is recognizing that not every process should be automated simply because the technology exists. Cleanroom requirements, validated sanitation procedures and manual quality activities often require a more selective approach.

Organizations should begin by identifying where automation delivers meaningful operational value without introducing unnecessary complexity or regulatory risk.

Automation in life sciences should not be about keeping pace with other industries. Instead, it should be part of an organization's broader operational strategy to build manufacturing operations that are resilient, flexible and capable of responding to changing products, evolving demands and increasingly complex supply chains all while continuing to meet the industry's high-quality standards.

Cate Davis, Miebach Consulting global lead pharma and life sciences, North America